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1. Introduction 
Hepatocellular carcinoma (HCC) is responsible for significant morbidity and mortality in 
cirrhosis and also accounts for between 85% and 90% of primary liver cancer (Caldwell & 
Park 2009; Hussain & El-Serag 2009; Tandon & Garcia-Tsao 2009). Most of HCC in the world 
occur in the setting of cirrhosis and over half-million of people develop liver cancer every 
year and an almost equal number die of it (Caldwell & Park 2009; Hussain & El-Serag 2009). 
Liver cancer prognosis is determined by factors related to the tumor (etiologies) and factors 
related to the cirrhosis i.e. parameters of liver dysfunction (CLIP 1998; Llovet et al., 1999; 
Okuda et al., 1985; Tandon & Garcia-Tsao 2009). During the last 30 years the HCC-incidence 
rate increased dramatically, despite the development of the HBV-vaccine and the program 
for newborn vaccination against HBV, developed in European and Asian countries (El-Serag 
et al., 2003; Hussain & El-Serag 2009). 
Since 1997, and after implementing a program for vaccination of newborns against HBV, 
Chinese and Japanese populations began to show a decrease in HCC incidence, especially 
among males (Plymoth et al., 2009; Yu S. Z. 1995). In the other hand, HCV-infection is rising 
around the world (Davila et al., 2004; Kong S. Y. et al., 2009; Min et al., 2009; Yoon et al., 
2009; Yu M. L. & Chuang 2009) counter balancing the benefit effects of HBV-vaccination. 
This increase in incidence rate is observed through the world and it does not belong to a 
specific region. For example, the USA and Europe have the same positive incidence slope 
(Davila et al., 2004; Donato et al., 2006; El-Serag 2002; El-Serag 2004; El-Serag et al., 2003; 
Hassan et al., 2002; Hussain & El-Serag 2009; Scatton et al., 2009; Wu et al., 2000). The 
etiologies of HCC remain the same; the most important causes are the HBV and HCV 
infections, heavy alcohol consumption, aflatoxin B1, age and gender (males are more 
susceptible than females), race (Asian and African over 20 years old) , tobacco consumption 
and obesity associated with non-alcoholic fatty liver disease and the increase of the Diabetes 
II mellitus that rise the risk factor between 2 and 3, genetic hemochromatosis, primary 
biliary cirrhosis, alpha1-antitrypsin deficiency and autoimmune hepatitis (Banks et al., 2006; 
Borgen et al., 1998; Bostick et al., 1998; Caldwell & Park 2009; CLIP 1998; Collier & Sherman 
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1998; Davila et al., 2004; Donato et al., 2006; El-Serag 2002; El-Serag 2004; El-Serag et al., 
2003; Hassan et al., 2002; Hussain & El-Serag 2009; Idilman et al., 1998; Ishikawa et al., 1998; 
Jung et al., 1998; Llovet et al., 1999; Luzzi et al., 1998; Mendizabal & Reddy 2009; Mocellin & 
Hoon & et al., 2006; Mocellin & Keilholz & et al., 2006; Naume 1998; Naume et al., 1998; 
Okuda et al., 1985; Racila et al., 1998; Schutte et al., 2009; Wu et al., 2000; Yao D. F. et al., 
2007; Yu M. C. et al., 2000; Yu S. Z. 1995). 
Usually, HCC develops during a long process of inflammation and fibrosis, eventually 
leading to cirrhosis. (Britto et al., 2000; Hussain & El-Serag 2009; Idilman et al., 1998; 
McMahon 2009). The majority of liver masses are detected incidentally in asymptomatic 
patients. These lesions are identified using imaging tools such as ultrasonography (US), 
computed tomography (CT), and magnetic resonance imaging (MRI). A diagnostic approach 
to HCC has been developed based on the literature and expert consensus, and incorporates 
serology, cytohistology and radiology/imaging characteristics. (Assy et al., 2009; Bruix & 
Sherman 2005; Bruix et al., 2001; Byrnes et al., 2007; Durand et al., 2001; Gomaa et al., 2009; 
Hussain & El-Serag 2009; Mendizabal & Reddy 2009). 
HCC is one of the most aggressive cancers. Patients who show progress over the terminal 
stage have a 1-year survival of less than 10%. In the other hand, patients presenting as early-
stage HCC with preserved liver function, a solitary HCC or up to three nodules, each less 
than 3cm have 5-years survival figures up to 75%. The choice of the therapy and the 
prognosis are dictated by the severity of the liver function, portal hypertension and medical 
co-morbidities. National and internationals consensus were established to choose the best 
treatment adapted for each case and obtain the best prognostic. Milan, Barcelona Clinic 
Liver Cancer, Cancer of the Liver Italian Program, and San Francisco criteria had 
determined the prognosis of patients based on the number and size of nodules, the 
metastasis and the state of liver function leading to the best choice for the patient (Banks et 
al., 2006; Borgen et al., 1998; Bostick et al., 1998; Caldwell & Park 2009; CLIP 1998; Collier & 
Sherman 1998; Davila et al., 2004; Donato et al., 2006; El-Serag 2002; El-Serag 2004; El-Serag 
et al., 2003; Freeman R. B. et al., 2006; Hassan et al., 2002; Idilman et al., 1998; Ishikawa et al., 
1998; Jung et al., 1998; Llovet et al., 1999; Luzzi et al., 1998; Naume 1998; Naume et al., 1998; 
Racila et al., 1998; Sanchez Antolin et al., 2009; Yao D. F. et al., 2007). 
Based on these data, the physician can choose resection, orthotopic liver transplantation 
(OLT), percutaneous ethanol injection or radiofrequency ablation, chemoembolisation, 
systemic chemotherapy and symptomatic therapy. The first 3 treatments are potentially 
curative, the second following treatments are palliative and the last one usually is applied at 
the terminal stage of the disease (Mendizabal & Reddy 2009). At the time the HCC will be 
treated an important question that the physician has to face is the risk of recurrence and 
metastasis. To answer this question the best approach would be able to detect the circulating 
tumor cells in the bloodstream. 
2. Definition of CTC and HCC 
In the field of biology of tumors, some expressions have been coined for the different types 
of circulating cellular elements. The term circulating tumor cells (CTC) defines specifically the 
tumor cells detected in blood or lymphatic vessels. Circulating cells in the bloodstream or in 
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the lymphatic system are considered to be tumoral microemboli (CTM) and represent a 
collective migration. The terms disseminated tumor cells (DTC) and isolated tumor cell 
(ITC) can be also found in the literature, but are usually used to define the cells that can be 
detected in both the organs and the bloodstream. The word micrometastasis is usually used 
to indicate tumor cells found in distant organs. (Luzzi et al., 1998; Schuler & Dolken 2006; 
Zieglschmid et al., 2005). The presence of circulating tumor cells reflects the aggressiveness 
nature of a solid tumor. Many attempts have been made to develop assays that reliably 
detect and enumerate these cells. The clinical results obtained with such assays suggest that 
in some tumor types, CTC detection and identification can be used to estimate prognosis 
and may serve as an early marker to assess anti-tumor activity of treatment. In addition, 
CTC can be used to predict progression-free survival and overall survival. CTC are an 
interesting source of biological information in order to understand dissemination, drug 
resistance and treatment-induced cell death. (Alix-Panabieres et al., 2008; Braun et al., 2005; 
Curry et al., 2004; Mocellin & Hoon & et al., 2006; Mocellin & Keilholz & et al., 2006; Muller 
et al., 2005; Nakagawa et al., 2007; Pantel et al., 2008; Pantel & Woelfle 2005; Paterlini-
Brechot & Benali 2007; Riethdorf et al., 2008; Sleijfer et al., 2007; Strijbos et al., 2008; 
Willipinski-Stapelfeldt et al., 2005).  
In general, intra- or extrahepatic metastases appear at a late tumor stage or after treatment 
suggesting that earlier during the development of the HCC, the tumor spread circulating of 
liver-derived cells or circulating tumoral cells also named in literature “micrometastasis”. In 
HCC animal models showed that 10 to 10 000 CTC are capable to initiate new metastasis 
(Groom et al., 1999; Hermanek et al., 1999; Liotta et al., 1974; Luzzi et al., 1998). Even after 
curative resection, the tumor recurrence rate remains high. Although CTC detection has 
been applied and well documented in different types of cancer, especially breast cancer, 
CTC detection is not routinely performed in HCC follow-up and remains in the 
experimental field. However, CTC detection might bring new interesting information of 
metastatic process, might be used as diagnostic tool of early recurrence and may allow a 
better patient selection for liver transplantation. Mechanisms of tumor recurrence are still 
poorly understood. Several arguments point out that HCC tumor cells can infiltrate the 
blood system as shown by the presence of alpha-fetoprotein mRNA (Aselmann et al., 2001; 
Kamiyama et al., 1996; Kienle et al., 2000; Komeda et al., 1995; Lemoine et al., 1997; 
Matsumura 2001; Matsumura et al., 2001; Matsumura et al., 1995; Matsumura et al., 1994; 
Matsumura et al., 1999; Morimoto et al., 2005). CTC seem to be correlated with poor survival 
in many types of tumors (Aselmann et al., 2001; Kamiyama et al., 1996; Komeda et al., 1995; 
Lemoine et al., 1997; Matsumura et al., 1994; Morimoto et al., 2005).  
However, HCC circulating cells are still difficult to detect, and their presence and amount 
are poorly correlated with either long-term survival or recurrence in the setting of HCC. 
Given the lack of specific biological markers, few studies focused on CTC detection. The 
challenge of CTC detection is related to the requirement of both high sensitivity and 
specificity. A wrong labeling of ‘‘non-tumor cells’’ (epithelial non tumor cells or normal 
hepatocytes, for instance) as ‘‘tumor cells’ could generate poor clinical interest. 
Methods of CTC detection have to be highly sensitive and specific. The first technical 
challenge in this field consists of finding exceptional cells. Just a few CTC are mixed with 
the approximately 10 million leukocytes and 5 billion erythrocytes in 1 ml of blood. To be 
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useful, the method used to identify circulating tumor cells must also detect all tumor cells 
and discriminate them from non-tumor cells. (Alix-Panabieres et al., 2008; Becker et al., 2005; 
Braun et al., 2005; Curry et al., 2004; Mocellin & Hoon & et al., 2006; Nakagawa et al., 2007; 
Paterlini-Brechot & Benali 2007; Ross et al., 1993; Schuler & Dolken 2006; Smerage & Hayes 
2006). Before considering the technical problems, it is important to have circulating 
hepatoma-specific biomarkers to be able to detect the CTC and further to be useful to early 
diagnosis, monitoring metastasis or post treatment recurrences of HCC. 
Currently, CTC detection is mainly based on alpha-fetoprotein (AFP) messenger RNA 
(mRNA) assessment or quantification, and in few reported cases using cytomorphometric 
technology, especially the ISET devise. A high sensibility could be obtained using flow 
cytometry assays but high blood volumes (200 ml) and long analysis time (40 h for one 
sample) are required. Consequently, its use has been discouraged as a routine technique 
(Mejean et al., 2000). 
3. HCC markers and their application for CTC 
The hepatocellular carcinomas can synthesize various tumor-related proteins, polypeptides 
and isoenzymes more or less specific of the hepatoma tissues. It is important to detect CTC 
in the bloodstream or lymphatic system to have tumor specific markers of HCC. Finding 
one of these circulating proteins does not mean that there circulating tumor cells. 
3.1 Secreted proteins 
3.1.1 Relevance of cytokines in HCC circulating tumor cells 
Hepatocellular carcinoma tumor has shown to secret a lot of cytokines related to the 
development of the tumor, like vascular endothelial growth factor (VEGF), transforming 
growth factor-beta 1 (TGF-β1), Interleukin 8 (IL-8) or tumor-specific growth factor (TSGF). 
These serum markers are useful to follow-up the development and the prognosis of the 
HCC but useless to follow-up circulating tumor cells in blood (Zhou et al., 2006). 
3.1.2 The case of the serum AFP 
The serum -fetoprotein (AFP) levels show high levels in newborns and then declines 
progressively below 10 ng/ml in 300 days of life. An increase of serum AFP levels can be 
observed during pregnancy, and in patients with mucovicidosis, acute hepatitis (30%-50%), 
chronic hepatitis (15%-50%), cirrhosis (11%-47%) and other cancers (gastrointestinal, 
pancreatic, biliary, non-seminomatous germ-cell testicular, and germ cell ovarian). Serum 
level AFP sensitivity is between 39% to 64% with approximately 60% for a cutoff of 20 
ng/mL, and decrease to 22% if higher cutoff of 200 ng/mL is used (Bruix et al., 2001; Collier 
& Sherman 1998; Fujiyama et al., 2002; Okuda 1986; Saffroy et al., 2007; Trevisani et al., 
2001). AFP specificity is around 76%-91% with a low predictive value between 9%-32% 
(Bruix et al., 2001; Collier & Sherman 1998; Okuda 1986; Saffroy et al., 2007).  
In addition, the serum AFP level is correlated with the tumor size. 80% of small HCCs 
(<2cm) do not express AFP. In the other hand, AFP level can be elevated in patients with 
chronic liver disease with high degree of hepatocytes regeneration such as HCV-infection 
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that show a high level of AFP in absence of malignancy (Toyoda et al., 2004; Vejchapipat et 
al., 2004). For these reasons, some additional serological markers used in combination with 
AFP seem to improve the performance of this biomarker, especially in terms of sensitivity.  
Studies were done by using one or two more markers like des- carboxyprothrombin (DCP) 
also called prothrombin induced by vitamin K absence II (PIVKAII) and glycosylated AFP-
L3 (Lens culinaris Agglutinin-Reactive AFP) fraction serum levels to diagnose earlier HCC 
and increasing the sensitivity especially when HCC is associate with cirrhosis, HCV or HBV 
infection (Dohmen et al., 2003; Fujiyama et al., 2002; Gonzalez & Keeffe 2011; Lok et al., 2009; 
Min et al., 2009; Saffroy et al., 2007; Suehiro et al., 1994). But there is no study that correlates 
their serum levels and the circulating tumor cell during the HCC development. 
3.2 The mRNA markers 
In the next sections, we focus on and describe the most specific markers of messenger RNA 
used to detect CTC in hepatocellular carcinoma. 
3.2.1 Relevance of -fetoprotein (AFP) messenger RNA (mRNA) 
Initially, the albumin gene has been proposed as a biological marker to track CTC during 
HCC development but has been rapidly abandoned since many groups have reported 
illegitimate transcription of albumin gene in peripheral-blood leukocytes. The relevance of 
AFP mRNA as a marker of circulating tumor cells is better but is also controversial because 
these cells have not been further characterized and it has been shown that they may 
correspond to normal circulating hepatocytes (Lemoine et al., 1997; Louha et al., 1999; 
Minata et al., 2001). Furthermore, these tumor cells have mostly been sought and detected 
shortly after liver resection (Kienle et al., 2000; Lemoine et al., 1997; Louha et al., 1999; 
Matsumura et al., 1994; Minata et al., 2001). This finding suggests that CTC could spread 
following liver mobilization or manipulation. Although the mechanisms leading to intra and 
extrahepatic recurrences are still unknown, some observations suggest that bone marrow 
(BM) could also be a specific reservoir of CTC. Indeed, several reports have suggested that 
tumor cells are of BM origin (Agarwal et al., 2004; Houghton et al., 2004; Sell 2002). Hepatic 
tumor stem cells may take advantage of the potential for stem cell support of the BM 
microenvironment. The amplification of AFP mRNA by means of reverse transcription 
(RT) and a nested polymerase chain reaction (PCR) is the highly sensitive method for the 
detection of residual HCC cells in peripheral blood. The qualitative (positive versus 
negative) detection of HCC circulating tumor cells in blood samples from individual 
patients is of limited value in predicting the risk of disease progression. Because the level 
of AFP mRNA is increased in HCC tissue compared with in normal hepatocytes, the 
quantification of AFP transcripts seems to be a more reliable indicator of disease 
progression. A more highly sensitive assay based on TaqMan® technology to quantify 
AFP mRNA in “real time” should be preferred (Cheung et al., 2006; Gross-Goupil et al., 
2003; Lu Y. et al., 2007; Matsumura 2001). Even using this methodology, reported results 
are not homogeneous and contradictory (Bruix et al., 2001). The main studies which have 
evaluated AFP mRNA are summarized in Table 1. The false-positive results can be 
obtained using AFP mRNA. 
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Author PCR Sensitivity Cases Samples Positivity Predictability 
of recurrence 
(Kamiyama et 
al., 1996) 
qRT-PCR 1 CHC/ l07 37
136
Blood
BM
18%
28%
No 
Yes 
(Morimoto et 
al., 2005) 
qRT-PCR 1 CHC/106  38
25
Blood
BM
10 %
48%
Yes 
No 
(Kienle et al., 
2000) 
nRT-PCR 5 cells/ 1mL 24 Blood
BM
29%
43%
Suspect 
(Aselmann et 
al., 2001) 
Competitive 
RT
10 cells/ 9 mL 22
11
Blood
BM
26%
45%
NA 
(Sutcliffe et al., 
2005) 
RT-PCR NA 18 BM 93% No 
(Matsumura et 
al., 1995; 
Matsumura et 
al., 1994) 
nRT-PCR 33 Blood 52% Extrahepatic 
metastases 
(Komeda et 
al., 1995) 
nRT-PCR 15 cells/mL 64 Blood 36% Extrahepatic 
metastases 
(Lemoine et 
al., 1997) 
nRT-PCR 1CHC/105
mono
20 Blood 25% No 
(Miyazono et 
al., 2001) 
nRT-PCR 10-6μg/μLof 
RNA
33 Blood 54% Yes 
(Ijichi et al., 
2002) 
nRT-PCR 1CHC/105
mono
87 Blood 36% Yes 
(Witzigmann 
et al., 2002) 
nRT-PCR 1 CHC/107
mono
85 Blood 26-45% No 
(Gross-Goupil 
et al., 2003) 
RT-PCR 1 CHC/106 52 Blood 25% No 
Table 1. Evaluation of serum alpha-fetoprotein as a marker of circulation tumor cell in 
different hepatocellular carcinoma studies. nRT-PCR, nested RT-PCR; qRT-PCR, 
quantitative RT-PCR. 
3.2.2 Transforming growth factor beta-1 (TGF-β1) mRNA 
The levels of circulating TGF-β1 and TGF-β1 mRNA were significantly higher in the HCC 
patients than any other group of patients. The sensitivity and specificity of circulating TGF-
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β1 level (>1.2 µg/L) were 90% and 94% for HCC diagnosis, but no significant correlation 
was found between TGF-β1 expression an AFP levels or tumor size. The combined detection 
of TGF-β1 and serum AFP could raise the detection rate of HCC up to 97%. Both of 
circulating TGF-β1 and TGF-β1 mRNA could be used as sensitive biomarkers for diagnosis 
and prognosis of HBV-induced HCC (Dong et al., 2008; Wang Y. L. et al., 2007). 
Unfortunately, TGF-β1 mRNA was poor studied and further investigations have to be done 
to use circulating TGF-β1 mRNA as a marker of circulating tumor cells in HCC. 
3.2.3 Insulin-like growth factor (IGF)-II mRNA 
Studies using amplified fragments of IGF-II mRNA by RT-PCR showed that the lowest 
sensitivity with 2 ng/L of total RNA. Dong et al., showed that the positive frequencies of 
IGF-II mRNA were 100% in HCC, around 50% in paracancerous and 0% in noncancerous 
tissues respectively. But, the positive frequency of circulating IGF-II mRNA was 34% in 
HCC, and no amplification was found in other liver diseases, extrahepatic tumors, and 
normal control, meaning that IGF-II is specific of the HCC but nor really sensitive. 
Associated to other circulating markers IGF-II can be helpful to detect CTC. The circulating 
IGF-II mRNA was correlated with the stage of HCC (incidence=100%) with extrahepatic 
metastasis, and 35% with AFP-negative. No difference was found between tumor size and 
circulating IGF-II mRNA (Dong et al., 2005; Wang Y. L. et al., 2007) but these results are 
controversial (Qian et al., 2010). 
3.2.4 Alpha-albumin (ALF) mRNA 
For more than a decade, we know that mRNAs of hepatocytes-specific albumin genes are 
detected in peripheral blood by RT-PCR. It was shown that there is evidence that detection 
of albumin mRNA associated with the detection of AFP mRNA is strongly associated with 
the presence of metastases (Hillaire et al., 1994; Kar & Carr 1995; Komeda et al., 1995; 
Matsumura et al., 1995). Wong et al., showed that circulating hepatocellular carcinoma cells 
can be detected and be semi-quantified by albumin RT-PCR (Wong et al., 1997). On the 
other hand, Wu et al., showed that, the down regulation of alpha-albumin (ALF) specifically 
in HCC circulating cells can be used has a specific marker to discriminate the normal 
hepatocellular circulating cells that express abundantly ALF. RT-PCR ALF in association 
with RT-PCR AFP have been proposed to distinguish normal or malignant hepatocytes in 
peripheral blood, but the interpretation of the results is still debated (Resto et al., 2000). 
3.2.5 Prostate-specific antigen (PSA) and mRNA PSA 
The Prostate-Specific Antigen (PSA) had shown to be well-established reliability marker and 
remained a valid prostate marker in patients with acute hepatitis and HCC (Malavaud et al., 
1999). But these results are controversial, PSA and mRNA PSA seem to don’t be specific to 
the tissue and frequently detected in peripheral blood cells from healthy patients (Ishikawa 
et al., 1998). In addition, like the cytokines, serum PSA cannot be used as hepatocellular 
carcinoma marker for circulating tumor cells. 
3.2.6 Heat shock protein (HSP) 
Heat shock proteins (HSP) are stimulated under perturbation or stressors by the tissue. HSP 
are ubiquitous molecules and can be also expressed during carcinogenesis. Different HSP 
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have been related to the development of the hepatocellular carcinoma like gp96 or GRP94, 
HSP70 and HSP27, but none of them were used as a specific marker of circulating tumor cell 
(Wang Y. L. et al., 2007). 
3.2.7 Human telomerase reverse transcriptase mRNA or hTERT mRNA 
Human telomerase is a ribonucleic protein composed by the association of three structures: 
human telomerase RNA component (hTERC); human telomerase-associated protein 1 
(hTEP1); and human telomerase reverse transcriptase (hTERT). hTERT is the catalytic unit of 
the complex. Also, telomerase is expressed in embryonic cells, in most human cancer cells or 
immortal cell lines, but not in normal somatic cell lines or tissues. For these reasons, hTERT 
was investigated as a marker of diagnosis and prognosis of HCC, but the results are 
controversial and appear that false-positive results can be observed because of lymphocytes, 
precancerous liver parenchymal cells and micrometastasis maybe responsible (for review 
(Grizzi et al., 2007; Wang Y. L. et al., 2007; Zhou et al., 2006)). Recently, Kong et al., 
investigated hTERT in peripheral blood in HCC from 343 Korean patients. There is no 
association between hTERT expression and clinical features and nor relationship between 
AFP and hTERT mRNA. Their conclusion is that AFP and hTERT mRNA expression in 
peripheral blood is useless as HCC prognostic markers (Kong S. Y. et al., 2009). 
3.2.8 Cancer-testis antigens (CTA) 
Cancer-testis antigens (CTA) represent a category of tumor-associated antigens normally 
expressed in male germ cells but not in adult somatic tissues (Scanlan et al., 2002). CTA are 
heterogeneous group of antigens. Actually, more than 44 distinct CT “gene” or “antigen” 
families have been reported in literature. Certain CT gene families contain multiple 
members, as well as splice variants and today more than 89 distinct transcripts are known to 
be encoded by CT genes (Scanlan et al., 2002). A number of CT antigens have been found 
expressed with high percentage and specificity in HCC. The expression of the CT antigens 
mRNA was investigated by Wu et al., in the HCC and corresponding peripheral blood of 37 
patients with HCC, 15 samples of cirrhotic tissues and 15 normal tissues with the same 
method. Two CT antigens SSX-2 and SSX-5 showed in this study high specific and high 
frequent expression only in HCC tissues. In corresponding peripheral blood of HCC tissues, 
the positive expressions rate of these two CT antigens mRNA was not very high (Benoy et 
al., 2006). The same group of researchers used another two CT antigens SSX-1 and NY-ESO1 
in the same group of patients and with the same methods (RT-PCR) with the corresponding 
peripheral blood. They showed that SSX-1 can be potential used in peripheral blood, with 
short term recurrence rat at 46% (6/13) in patients whose peripheral blood expressed SSX-1 
mRNA, while the recurrence rate in patients with negative SSX-1 mRNA was 28.6% (4/14) 
(Bergamaschi et al., 2008). In another study, Peng et al., showed that specific expression of 
CT antigens was observed in AFP-negative HCC, suggesting the application of their mRNA 
as tumor markers to detect circulating HCC cells (Peng J. R. et al., 2005). Yang et al., showed 
that FATE/BJ-HCC-2 (another CTA) mRNA expression was detected in the peripheral 
blood mononuclear cells (PBMCs) of 46.67% patients, whose HCC tissue samples were cut 
off and positive for FATE/BJ-HCC-2 mRNA, which implicated tumor cell dissemination in 
blood circulation and related to the metastasis of HCC. These studies suggest that CT 
antigens expressions can be used in peripheral blood to detect HCC circulating cells, but 
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also can be associated to the research of AFP mRNA to increases the specificity and the 
frequency of the method. This group of markers seems promising and further studies have 
to be done first to determine the panel of CT antigens to be used as markers of HCC 
circulating cells. 
3.3 New approaches 
To attempt the lack of CTC markers, new techniques and technologies are used such as 
microarray/mRNA large analyses, proteomic and “secretome” analyses and finally 
microRNA testing.  
3.3.1 Microarray/mRNA large analyses 
DNA chips were used to measure and find new markers to diagnose HCC, but also to use 
these as CTC markers. The studies showed the expression of mRNAs for members of the 
glypican and syndecan families of heparin sulfate proteoglycans such as GPC3 can be a 
good CTC marker that can be used in human or in mouse models (Suzuki et al., 2010; Yao 
M. et al., 2011). Another interesting marker was discovered called Snail. Snail mRNA was 
study in blood of patients with HCC and metastasis (Min et al., 2009). But further 
investigation has to be done to figure out the specificity and the sensitivity of those markers. 
3.3.2 Proteomic and secretome analyzes 
In the process to find new markers for CTC, a number of teams started to work with 
proteomic analysis such as quadrupol IT-TOF, SELDI- TOF MALDI-TOF/TOF mass 
spectrometry. Their objective is tracking earlier the development and the progression of the 
HCC. Few markers or group of markers were identified by these methods such as the usual 
markers AFP, AFP-L3, TGF-1, and PIVKA-II but also vitronectin, alpha-1-fucosidase (AFU) 
and DCP, Golgi protein-73 (GP73), hepatocyte growth factor (HGF), and nervous growth 
factor (NGF) (Dai et al., 2009; Donati et al., 2010; Liu X. & Wan & et al., 2011; Paradis et al., 
2005; Peng X. Q. et al., 2009; Poon et al., 2003; Zinkin et al., 2008). 
Interestingly, the proteomic analyses were able to detect new markers in the serum secreted 
(which is called “secretome”) by the carcinoma cells (Makridakis & Vlahou 2010; 
Malaguarnera et al., 2010; Niu et al., 2010). Over 90 proteins in some studies compiled with 
high powerful biocomputational analysis where identified and used to diagnose HCC early 
(Dai et al., 2009; Paradis et al., 2005; Poon et al., 2003; Zinkin et al., 2008). Unfortunately 
these studies did not analyze the real usefulness of these markers to identify CTC in the 
patients with HCC. 
A sub-group of HCC was identified by these techniques expressing stem cell markers 
(CD133, CD90, CD44, EpCAM, CD13 or neural cell adhesion molecule; NCAM) defining 
what is called now liver cancer stem cell but unfortunately these markers were not studied 
in the area of circulating tumor cells (Chiba et al., 2009; Huang & Geng 2010; Liu L. L. & Fu 
& et al., 2011). They are very promising markers. Another group of markers very promising 
to detect CTC belongs to the chemokine receptors such as CXCR4, CX3CR1 and CCR6 
express during HCC progression (Huang & Geng 2010; Li et al., 2010), but none of them 
were tested during a clinical trial. 
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3.3.3 MicroRNA markers: A new hope 
Around 28 years ago, microRNA (miRNA) was discovered and showed the regulation of 
genes (Lee et al., 1993; Reinhart et al., 2000) such as oncogenes or tumor suppressor genes at 
the level of the mRNA. More than 35 studies focused on the identification of miRNA or a 
group of miRNAs to be used as marker of early diagnosis or metastasis. miR-122/-122a, 
miR-221/222, miR-145, miR-146a, miR-26 (NFB pathway), miR-199a-3p (mTOR pathway) 
and miR-26 (MYC pathway) were strongly linked to the development and metastasis of the 
HCC. Also a group of miRNAs were used to identify and classify HCC (Hoshida et al., 2010; 
Ji & Wang 2009; Kerr et al., 2011; Kojima et al., 2011; Kong G. et al., 2011; Sato et al., 2011), 
but non of them were used as a CTC marker and tested during a clinical trial. 
3.4 Conclusion 
In Conclusion, we can observe that not too many specific HCC markers are available and 
useful for the detection of the CTC. This is certainly due to the heterogeneity of the 
hepatocellular carcinoma. The most important marker used in clinical routine is the 
detection of serum AFP mRNA expression (Table 1). But this marker is not expressed in all 
HCC and by consequence in all CTC leading false negative results. Some propose to 
combine the research of more than one marker to increase the specificity and the sensitivity 
of CTC detection method. One of promising marker is Cancer-Testis Antigens but more 
studies need to be done to select one or more CTA combined (or not) with the detection of 
the AFP mRNA expression. As we notice previously, CTC are very rare in peripheral blood. 
We saw also that real-time polymerase chain reaction is a method that in addition to be 
specific by the nature of the primers used, it can amplify the signal by increasing the 
number of copies of mRNA originally presents in the sample. But before using RT-PCR, it’s 
necessary to concentrate the number of CTC from the peripheral blood in a smaller volume. 
The next chapter will describe these methods. 
4. Enrichment of the sample 
CTC are usually detected in the peripheral circulation, but we can find CTC in other body 
fluids like the cerebrospinal fluids or the urines. The limitations to discover the CTC in these 
fluids are the same than in the blood circulation. However, it is possible to extract a 
relatively big amount of blood without harming the patient and much easier. 
We will focus on the methods of CTC detection in the blood. As we describe above, CTC 
in the peripheral circulation occur at an estimated number of one CTC per 105-7 peripheral 
blood mononuclear cell or PBMC. Because of the scarcity of the target cells, it is necessary 
to concentrate the sample. Since enrichment will inevitably be accompanied by some loss 
of CTC, irrespective of the method, some essays are performed directly in whole blood 
(Lu Y. et al., 2007). 
Two different groups of techniques can be used to enrich samples, the non-specific and 
the specific enrichment techniques. The non-specific enrichment techniques use physico-
chemical CTC properties (size, density, etc). The specific enrichment technique use 
markers expressed by the CTC. The advantages of the non-specific and specific 
enrichment techniques are summarized in the Table 2 and described in the following 
paragraphs. 
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Methods of 
Enrichment 
Advantages Disadvantages References 
Non-Specific 
Density 
(OncoQuick®, 
Ficoll, UNI-
Set®) 
1. Isolation of whole and living 
CTC, 
2. Can use another method of 
enrichment more specific 
(immunomagnetic beads), 
3. Cytopathology, Cytological 
staining, ICH, FISH...etc can be 
performed, 
4. RNA, DNA extractions 
followed by RT-PCR or PCR 
respectively can be done.  
1. Non-specific,
2. Rare CTC can be lost in 
the plasma fraction or 
trapped among 
erythrocyte and 
neutrophils, 
3. Low and variable 
sensitivity, 
4. Depends of the type of 
CTC, temperature, 
centrifuge, 
5. Expensive. 
(Balic et al., 
2005; Becker 
et al., 2005; 
Mankin et al., 
2002; 
Paterlini-
Brechot & 
Benali 2007) 
Size 
(MEMS, ISET) 
1. Easy
2. Precise counting of the cells 
per ml of blood, independently 
of the volume of the blood 
treated, 
3. Allows Cytopathology, 
Cytological staining, ICH, 
FISH...etc, 
4. Allows Microdissection 
followed by  
5. RNA, DNA extraction follow 
by RT-PCR or PCR respectively 
6. Avoids multiple steps, 
7. Increases sensitivity (1 single 
CTC can be detect from 1ml of 
blood). 
1. Non-specific,
2. CTC can go through 
the filter, 
3. Cells can be damaged, 
4. Expensive, but less 
than the 
immunomagnetic beads. 
(Li et al., 2010; 
Mejean et al., 
2000; 
Paterlini-
Brechot & 
Benali 2007; 
Pinzani et al., 
2006; Vona et 
al., 2004) 
Cytospin 1. Easy,
2. Allows Cytopathology, 
Cytological staining, ICH, 
FISH...etc, 
3. Allows Microdissection follow 
by  
4. RNA, DNA extraction follow 
by RT-PCR or PCR respectively.
 
1. Increase the mortality 
of the CTC. 
(Becker et al., 
2005; Farina et 
al., 2004; 
Kallergi et al., 
2008; 
Kollermann et 
al., 1999; 
Saraiva-
Romanholo et 
al., 2003) 
Lysis Buffer 
(Qiagen) 
1. Easy,
2. The cells harvested by this 
method can be re-enriched or 
analysed by the methods 
already described, 
3. Low cost. 
1. Increase the mortality 
of the CTC, 
2. Low sensitivity. 
(Aryal et al., 
2004; Khan et 
al., 2000; 
Wharton et 
al., 1999) 
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Specific 
ImmunoMagn
etic Beads 
(MACS 
system, 
CellSearch) 
1. Specific 
2. Morphological analysis of 
CTC, Cytopathology, 
Cytological staining, ICH, 
FISH...etc, 
3. Multiple labelling of antigens 
on CTC, 
4. Direct quantification of CTC. 
1. Subjective analyses for 
CTC identification, 
2. Time-consuming 
screening of tumor cells, 
3. Need specific 
marker(s) and antibody 
available, 
4. Expensive. 
 
(Alix-
Panabieres et 
al., 2005; Alix-
Panabieres et 
al., 2008; Alix-
Panabieres et 
al., 2007; 
Czerkinsky et 
al., 1983) 
EPISPOT 1. High sensitivity, 
2. Detection of viable CTC, 
3. Detection of secreted proteins.
1. Protein must be 
actively secreted, shed, or 
released, 
2. No identification and 
isolation of secreting cell 
possible. 
(Alix-
Panabieres et 
al., 2005; Alix-
Panabieres et 
al., 2008; Alix-
Panabieres et 
al., 2007; 
Czerkinsky et 
al., 1983) 
FACS 1. High sensitivity, 
2. Technique for counting, 
examining, and sorting 
microscopic particles (CTC) 
suspended, 
3. Simultaneous multiparametric
analyses of the physical and/or 
chemical characteristics. 
1. Need the apparatus, 
2. High cost. 
(Lobodasch et 
al., 2007; 
Mankin et al., 
2002; 
Pachmann et 
al., 2005) 
FAST 1. High sensitivity, 
2. Can detect rare events. 
 
1. Fluorescent dye-
conjugated antibodies, 
2. Specificity depend of 
the antibodies, 
3.Very expensive. 
(Curry et al., 
2004; Hsieh et 
al., 2006; Lu Y. 
et al., 2007; 
Pinzani et al., 
2006) 
CTC-Chip 1. High sensitivity, 
2. Detection of viable CTC. 
1. Detect only 
cytokeratin+-CTC, 
2. Need to control 
precisely laminar flow 
conditions, 
3. Expensive. 
(Alix-
Panabieres et 
al., 2008; 
Nagrath et al., 
2007) 
Table 2. Summary of advantages and disadvantages of the methods of CTC enrichment. 
CTC, circulating tumor cell; CTC-Chip, circulating tumor cell chip; EPIPSPOT, epithelial 
immunospot; FACS, Fluorescence-activated cell sorting = flow cytometric; FAST, fiber-optic 
array scanning technology; ICH, immunocytochemistry; ISET, isolation by size of epithelial 
tumor cells; MACS, magnetic cell sorting; MEMS, micro-electro-mechanical system. 
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4.1 The non-specific enrichment techniques 
4.1.1 Density gradient(s) centrifugation 
The tumor cells, epithelial cells, platelets and low density leukocytes from leukocytes and 
erythrocytes can be separated by the propriety of their particular density (Table 2). Briefly, 
each cell type has their own density and the assumption of the methods is to put the cells in 
a buffer with a specific kind of density that usually corresponds to the density of the cells 
(CTC) that we want to isolate. Density gradient centrifugation is the preferred method to 
purify cells, subcellular organelles and macromolecules. Density gradients can be generated 
by placing layer after layer of gradient media such as sucrose in a tube with the heaviest 
layer at the bottom and the lightest at the top in either a discontinuous or continuous mode. 
The cell fraction to be separated is placed on top of the layer and centrifuged. Density 
gradient separation can be classified into two categories: 1). Rate-zonal (size) separation. 2). 
Isopycnic (density) separation.  
Rate-zonal separation takes advantage of particle size and mass instead of particle density 
for sedimentation. The examples of common applications include separation of cells, cellular 
organelles such as endosomes or separation of proteins, such as antibodies (Rickwood D; 
Grahm J. M. 2001). 
Criteria for successful rate-zonal centrifugation are:  
- Density of the sample solution must be less than that of the lowest density portion of 
the gradient. 
- Density of the sample particle (CTC) must be greater than that of the highest density 
portion of the gradient.  
- The pathlength of the gradient must be sufficient for the separation to occur. However, 
if too long runs are performed, particles may all pellet at the bottom of the tube.  
In isopycnic separation, a particle of a particular density will sink during centrifugation 
until a position is reached where the density of the surrounding solution is exactly the same 
as the density of the particle. Once this quasi-equilibrium is reached, the length of 
centrifugation does not have any influence on the migration of the particle. A common 
example for this method is separation of nucleic acids in a CsCl gradient. A variety of 
gradient media can be used for isopycnic separations (Rickwood D; Grahm J. M. 2001). 
Criteria for successful isopycnic separation: 
- Density of the sample particle must fall within the limits of the gradient densities.  
- Any gradient length is acceptable.  
- The run time must be sufficient for the particles to band at their isopycnic point. 
Excessive run times have no adverse effect (Ford 1991; Graham 1997; Rickwood David. 
1992; Rickwood David, Ford T., Steensgaard Jens. 1994; Rickwood D; Grahm J. M. 2001).  
In the context of the CTC enrichment by centrifugation the isopycnic separation is the 
method usually used. The cells that have a density higher than the density of the buffer 
will stay in the bottom of the tube. If the density of the cells is lower than the buffer, they 
will remain on the top of the liquid, forming a ring. On the contrary, if the density of the 
cells is the same than the buffer, the cells will form a ring in the middle of the tube. A well 
known example of the method is the commercial buffer FICOLL™ tube (Amersham 
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Biosciences AB) or Lymphoprep® (Nicomed) to separate the red blood cells from the 
other cells including CTC (Table 2). 
OncoQuick® (Greiner) method uses a specific buffer able to isolate the CTC (Balic et al., 
2005; Mankin et al., 2002; Paterlini-Brechot & Benali 2007). These methods are usually fast 
but expensive and found in a context of clinical laboratory used in routine diagnosis (Table 
2). Alternative and cheaper methods can be used by preparing in the laboratory the 
gradient/density buffers. The same tube can contain one, two or three gradient buffers to 
increase the specificity of the separation between the different cells present in the blood 
(Gertler et al., 2003; Paterlini-Brechot & Benali 2007; Racila et al., 1998; Zach & Lutz 2006).  
4.1.2 Lysis buffers 
The content of different cells has different osmotic pressures. It is possible to expose the 
samples to buffer(s) that can be hypo-or hyper osmotic to any cell different to the target 
cells. After the lysis step the mix is centrifuged and the pellets will contain the CTC. Some 
companies provide a kit with lysis buffers ready to use. After lysis, the next step is the 
extraction of DNA or RNA (e.g. Red Lysis Buffer from Qiagen or Panomics) or the extracted 
cells can be purified by immunomagnetic beads enrichment (Aryal et al., 2004; Khan et al., 
2000; Wharton et al., 1999). However, lysis buffer can induce the death of a lot of cells 
including the CTC and it is not appropriate if the sample contains few CTC leading to false 
negative results. 
4.1.3 Cytocentrifugation (cytospin) 
The cytocentrifugation was designed for hypocellular fluids; it spins at lower speeds and 
has more gradual acceleration and deceleration than normal centrifuges. Some are able to 
deposit cells directly onto a slide for examination. Cytocentrifugation could be used in 
research purposes and is also widely used in the routine surgical pathology practice. This 
method is fast and affordable (Becker et al., 2005; Kallergi et al., 2008; Kollermann et al., 
1999; Molnar et al., 2001). 
Methods to identify CTC can after be used (see below). As it occurs with magnetic beads, 
cytospin increases mortality of the target cells (Table 2). Because enrichment by 
cytocentrifugation is a critical step,  addition of 10 % buffered formaldehyde solution added 
to the blood sample can preserve morphology of the cells and will certainly preserve nucleic 
acids integrity (Farina et al., 2004), but the disadvantage of this method is that formaldehyde 
kills the cells (Table 2). Liquid based cytology (LBC) using a filtration process and computer 
assisted thin layer deposition of cells has been developed as a replacement for 
cytocentrifugation and/or smearing, owing to its improved cell recovery capabilities and 
better cell preservation. In most published series, LBC allows a good interobserver 
reproducibility. In the urine, processing by the Cytyc ThinprepH 2000 system (Cytyc Corp, 
Boxborough, Massachusetts, USA) is a method that combines centrifugation and filter 
transfer methods. The vial containing CTC is placed into a processor (the machine which 
prepares the smears) together with a glass slide and filter mechanism. The processor 
immerses the filter assembly into the vial and spins it at a high speed to ensure an even mix 
of the cells and to break up large cell groups. The fixative is then sucked through a filter 
membrane which traps the cells but allows fluid through. When an adequate number of 
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cells have been deposited on the filter, the processor detects a drop in the suction pressure 
and stops drawing fluid through the filter. It then applies the filter to a specially prepared 
glass slide and transfers the cells across. The slide is deposited into a vial of fixative (paraffin 
10%) from which it is subsequently taken out and stained. It results in increased cellularity 
and a pronounced reduction of debris, red blood cells (RBC), and crystals (Papillo & Lapen 
1994; Piaton et al., 2004; Wright & Halford 2001).  
There are several advantages to this system. One is that it produces a thin layer of cells 
which is easier to evaluate than a thick smear. The morphology of the cells is also better. 
In addition, the entire cell sample is captured in the fixative vial which leads to a more 
representative smear being prepared. One of the most important advantages of this test is 
that the material that is left over after a smear has been prepared can be used for 
adjunctive testing. A further advantage is that the smears may be initially subjected to 
image analysis. Computer software “reads” the smears and registers the co-ordinates of 
the fields with what it regards as the most abnormal cells. On review the system directs 
the cytotechnologists to these fields where they are evaluated. This can cut down on 
technologists’ screening time (Table 2). 
There are also some disadvantages, which include increased manpower needed to prepare 
the smears, and the dependence of smear preparation on the instrument. This technique 
cannot be used directly from blood samples. The red blood cells need to be eliminated by 
FICOLL® method for example and after the sample can be processed by this technique 
(Table 2). This method is usually used for urine or ascites samples. However, optimization 
of cell capture and fixation can be achieved by methods other than Cytyc Thinprep LBC, 
particularly while using meticulous modern cytocentrifugation methods in the study of 
hypocellular fluids like in urine for the bladder cancer (Piaton et al., 2004; Wright & Halford 
2001). In their study, Piaton et al., conclude that Cytyc Thinprep LBC and modern 
cytocentrifugation techniques are appropriate methods for cytology based molecular 
studies. From an economical point of view (standard cytocentrifugation are around $ 538 
compared to Cytyc ThinprepH $ 1,278 ), and taking into account the value of a meticulous 
technique, cytocentrifugation with disposable sample chambers remains the quality 
standard for current treatment of urinary samples for example (Piaton et al., 2004). 
4.1.4 Filters 
A non-specific method of enrichment using filters can captured the cells with a certain size. 
The cells captured on the filter can after be transferred and analyzed on a slide. In this case 
the samples can come from blood or body fluids (urines, cerebrospinal fluid or ascites). We 
will describe two kinds of methods using this technology and usually used to isolate CTC 
(Table 2): the Isolation by Size of Epithelial Tumor Cells (ISET) method and the Micro-
Electro-Mechanical System (MEMS). 
The Isolation by Size of Epithelial Tumor Cells (ISET) method (Metagenex, Paris, France, 
www.metagenex.fr) separates cells by size with a filter. Cells larger than 10 µm, including 
tumor cells from carcinomas, are enriched from leukocytes (erythrocytes are lysed, see 
above) on a filter. Enriched cells are stained on the filter and CTC are precisely counted after 
cytopathological evaluation. The cells on the filter can be also studied by immunolabelling, 
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FISH, TUNEL and molecular analysis. Molecular analysis can be performed specifically to 
CTC after laser microdissection. The filter can be also mounted between slide and coverslip 
for routine microscope observation and storage. Although promising, this method is 
expensive, time consuming and the filters are not easily available (Mejean et al., 2000; 
Paterlini-Brechot & Benali 2007; Pinzani et al., 2006). Cells should be better characterized 
using morphological methods that allow both detection and characterization. A second 
potential main advantage is that CTC could be compared to the primary tumor in order to 
better understand the mechanism of metastatic process. However, this approach has been 
rarely performed and neither firm recommendation nor conclusion could be drawn. This 
method has a high sensibility since one tumoral cell could be detect in 1 ml of blood. The 
technique also avoids damaging the tumor cell which can be diagnosed using a simple 
pathologist analysis. However, the pathologist should get used to this technique to avoid a 
misinterpretation with others types of cells. The use of ISET technology to detect and 
characterize CTC in HCC has been reported in one study. Vona et al., (Vona et al., 2004) 
reported that microemboli and isolated CTC could be detected in HCC patient. Presence of 
CTC was associated with a shorter survival. This work also showed the feasibility of 
molecular studies of individual circulating cells. Indeed, β-Catenin mutations were searched 
in samples of 60 single microdissected CTC. β-Catenin mutations were found in only 3 CTC 
that highlighted the weak impact of these mutations in the initial step of tumor cell invasion. 
Further studies are needed. 
The Micro-Electro-Mechanical System (MEMS)-based is a parylene membrane microfilter 
device for single stage capture and electrolysis of circulating tumor cells in human blood, 
and the potential of this device to allow genomic analysis. After the CTC are captured in the 
filter, electrical lysis of cells on membrane filter is applied and the DNA as well as RNA can 
be extracted and analyzed by PCR or RT-PCR respectively. CTC enrichment is performed by 
either gradient centrifugation of CTC based on their buoyant density or magnetic separation 
of epithelial CTC, both of which are laborious procedures with variable efficiency, and CTC 
identification is typically done by trained pathologists through visual observation of stained 
cytokeratin-positive epithelial CTC. These processes may take hours, if not days. The Micro-
Electro-Mechanical System (MEMS)-based makes the process simpler, faster and better to 
separate CTC (~90% recovery) from blood cells. Since enrichment will inevitably be 
accompanied by loss of CTC, irrespective of the exact method, some essays are performed 
directly in whole blood (Lu Y. et al., 2007). But the disadvantages of this technique are that 
morphology of the cells is lost, besides markers also and the capacity to count exactly the 
number of CTC (Table 2). 
4.2 The specific enrichment techniques 
The specific enrichment techniques can use specifically protein tumoral markers expressed 
by the CTC. These methods use antibodies against the protein tumoral markers coupled to 
steel beads, by applying a magnetic field the cells expressing the marker can be captured. 
Several immune-magnetic methods (MACS system, Deanabeads® Invitrogen, macro-iron 
beads, ferrofluid(colloidal iron)-based systems) to enrich the sample have been used 
successfully (Sergeant et al., 2008). We will describe the methods and their advantages and 
their disadvantages. Another approach to enrich the sample is to use the properties of CTC 
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to grow-up in a specific culture cell medium. A method (EPISPOT) that combines the 
capacity of CTC to secret specific markers and grow-up in specific cell medium was 
developed (see Table 2). 
4.2.1 Magnetic separation 
To use immune-magnetic detection system the first step is to deplete the whole blood of the 
red cells (by lysis buffers or density gradient) to obtain the PBMC. After, the magnetic 
particles coated and surrounded by a specific antibody are added to the PBMC supposing 
containing the CTC. Labeled cells are then collected by applying a magnetic force while non 
labeled cells are containing in the supernatant and are discerned. This use of magnetic beads 
to catch specifically CTC is called “positive selection” (Alix-Panabieres et al., 2008; Paterlini-
Brechot & Benali 2007; Sleijfer et al., 2007). 
Since a large number of leukocytes (potential source of false negative CTC) still remain 
trapped with the cells, some methods include a “negative selection”  of leukocytes (with 
anti-CD 45 beads for example) followed with a “positive selection” with antibodies specific 
to epithelial cells (EpCAM, CK) (Allard et al., 2004; Paterlini-Brechot & Benali 2007; Smirnov 
et al., 2005). The problem of this procedure is that gets ride the majority of leukocytes but 
still hold in non-malignant epithelial cells and loses tumor cells which do not express 
epithelial antigens and/or are lysed during the first step (Paterlini-Brechot & Benali 2007; 
Zigeuner et al., 2003). 
The methods using antibodies like immune-magnetic methods (MACS system, 
Deanabeads® Invitrogen, macro-iron beads, ferrofluid(colloidal iron)-based systems) to 
enrich the sample will induce false-positive extraction (Sergeant et al., 2008). For example, 
antibodies against cytokeratin (CK) or other epithelial-specific antigens have been reported 
to bind both specifically and non-specifically to macrophages, plasma cells and nucleated 
hematopoietic cells precursors. The non-specific binding of the antibodies involves Fc 
receptor-bearing leukocytes and monocytes or illegitimate expression of epithelial antigens 
in normal hematopoietic cells. Some of these positive cells are morphologically difficult to 
distinguish from CTC. Variable numbers of epithelial cells have been found in peripheral 
blood of subject without malignancy in some physio-pathological conditions like benign 
epithelial proliferative diseases, inflammation, surgeries and tissue trauma (Allard et al., 
2004; Becker et al., 2005; Goeminne et al., 2000; Naume et al., 2004; Naume & Espevik 1991; 
Paterlini-Brechot & Benali 2007). Moreover, epithelial CTC may lose epithelial markers 
during dissemination through the process called epithelial-to-mesenchymal transition 
(EMT). Since the epithelial markers that get lost during EMT may include markers used for 
CTC measurement, underestimation of the actual CTC number may occur, inducing de facto 
false negative results (Christiansen & Rajasekaran 2006; Paterlini-Brechot & Benali 2007; 
Sleijfer et al., 2007; Wang J. Y. et al., 2006; Willipinski-Stapelfeldt et al., 2005). In the case that 
the method induce false positive, the problem can be diminished avoided using a second 
marker or a full panel of  markers and techniques (see below) to characterize the CTC, like 
RT-PCR, immunocytochemistry or immunefluorescence, morphology by optical microscopy 
(Paterlini-Brechot & Benali 2007; Schuler & Dolken 2006; Sleijfer et al., 2007). In another 
hand, in the case of the false negative results the doubt persist, and only strict follow-up of 
the patient by repeating the detection of the CTC can potentially eliminate this doubt. No 
available antibodies are 100% tumor or tissue-specific (El-Serag 2004; Goeminne et al., 2000; 
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Paterlini-Brechot & Benali 2007). To isolate CTC a method using a ligand biotinylated was 
used. Biotinylated asialofetuin, a ligand of asialoglycoprotein receptor, was experimented 
and followed by magnetic separation or density gradient (Ficoll-Paque PLUS; GE 
Healthcare). The cells were identified by microscopy, FISH, immunofluorescence staining, 
flux cytometry and RT-PCR. This technique shows 81% specificity and 20 cells/5ml for the 
sensitivity (Xu et al., 2011). This promising approach has to be confirmed in a larger cohort 
of patients and still depend on the receptors expressed at the surface of the CTC. 
4.2.2 Culture of CTC 
After isolation of the CTC by the different methods described above, to increase the number 
of CTC, the primary tumor cells can be cultured in the specific culture medium (Allard et al., 
2004). The optimal conditions of culture growth and specially the culture medium leading 
the growth of the CTC, but not the other epithelial or non epithelial cells, have to be 
determined through an experiment. Some companies propose commercial kits. For example, 
The Cancer Cell Isolation Kit® from Panomics includes lysis buffer to increase the number 
of CTC. One of the main problems is that cultured cells can lose their original markers and 
derive. Mimicry of tumoral microenvironment in vitro is particularly difficult because for 
most tumors it is largely unknown. Another problem is that the samples containing the CTC 
are usually contaminated by stromal cells like fibroblasts, which create competition in the 
Petri dish. After few days, only the fibroblasts are present in the flask. 
4.2.3 Epithelial immunoSPOT (EPISPOT) 
A technique that allows the detection of only viable cells after a CD45+ cell depletion was 
introduced for CTC analysis from bone marrow aspirates and blood samples (Alix-
Panabieres et al., 2008; Alix-Panabieres et al., 2007; Braun et al., 2005). This technique was 
designated EPISPOT (epithelial ImmunoSPOT). It is a protein-secreting profiling based on 
the secretion or active release of specific marker proteins using an adaptation of the enzyme-
linked immunospot technology. As immunospots are the protein fingerprint left only by the 
viable releasing epithelial cells, a cell culture is needed to accumulate a sufficient amount of 
the released marker proteins (Table 2). The dying cells do not secrete adequate amounts of 
protein and are not detected (Alix-Panabieres et al., 2005; Alix-Panabieres et al., 2008; Alix-
Panabieres et al., 2007; Czerkinsky et al., 1983). This assay can also provide important 
information on the profile of secreted proteins potentially relevant for metastasis formation. 
However, this technique has still to be validated in large-scale clinical studies on cancer 
patients (Alix-Panabieres et al., 2008; Alix-Panabieres et al., 2007). After the enrichment and 
isolation of the CTC, the next step is to identify, characterize and finally enumerate them. 
The CTC can be identified by indirect or direct methods. But these important steps need 
tumor markers specific to the CTC seeked. 
5. Experimental models 
5.1 HCC mouse models 
Over decades, different HCC mouse models have been developed. 
Chemically induced HCC-models are diverse and not always reproducible. The chemicals 
usually used are diethylnitrosamine (DEN), peroxisome proliferators, aflatoxine, carbon 
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tetrachloride (CCl4), choline deficient diet or thiacetamide (Heindryckx et al., 2009; 
Weylandt et al., 2011). Transgenic mouse models were also developed, for example mice 
that contained HBV or HCV viruses or expressed specifically oncogenes (c-myc, c-myc + 
E2F1) or growth factors (TGF-, TGF- + c-myc, EGF, FGF19, GMNT, PDGF, 1-antitrypsin) 
(Heindryckx et al., 2009). Circulating tumor cells were not looked for in any of these animal 
models. One reason is the huge differences between models and the presence of specific 
markers for each situation. 
In order to solve these problems, researchers developed ectopic implantation that is fast and 
easy to perform. However, there is still many differences between the cell lines, no direct 
interaction with the liver tissues and difficulty to export to humans (Heindryckx et al., 2009). 
5.2 Orthotopic implantation 
Orthotopic implantation is a more suitable model because the cells are directly implanted in 
the liver tissue. Nevertheless, the procedure is challenging. There are big differences 
between cell lines and the choice of the markers is still limited (Heindryckx et al., 2009). 
Mechanisms leading to tumoral cells spreading are ill known. Currently, there are few 
models of orthotopic implantation of human tumoral cells (Scatton et al., 2008; Scatton et al., 
2006). An experimental model of human orthotopic HCC transplantation in NOD/SCID 
(non-obese diabetic/several compromise immuno-deficient) mice allows to generate and to 
modulate CTC (Scatton et al., 2008; Scatton et al., 2006). In this mouse model, tumoral 
spreading is an early event during tumoral development and the number of CTC is directly 
correlated to the tumor size. 
When injected under the liver capsule, a primary tumor develops and continuously yields 
circulating tumor cells. In addition, the CTC could be modulated after tumor removal. Liver 
tumor removal led to a very low level of tumoral cells in blood 30 days later. After complete 
tumor removal, the number of CTC significantly decreases but still remains detectable even at 
a low level. The FACS was used to detect CTC (detection of human HLA marker in mouse 
bloodstream). The reality of CTC was then demonstrated. An important finding is that the 
bone marrow could be early and permanently colonized by CTC (Scatton et al., 2006). 
5.3 Small imaging animal models 
With the recent development of the small imaging apparatus (example: IVIS Lumina II XR 
Imaging System, positron emission tomography) to study development and the progression 
of diseases in the live animals like rheumatism, a new area to study CTC in live animals is 
open. This technique was applied to study the CTC in ectopic or orthotopic HCC cell lines 
implantation. As we discuss above, the lack of specific HCC markers makes CTC studies 
very challenging. The idea is to bind luminescence tag (luciferase, yellow fluorescence or red 
fluorescence proteins) in the hepatoma cell lines injected in the liver that be detected by 
bioluminescence machine. For example, thymidine kinase-luciferase was placing under the 
transcriptional control of endogenous AFP promoter to develop a transgenic mouse model 
that injected with DEN will develop HCC (Lu X. et al., 2011). The development of the HCC 
was followed in the live animal by bioluminescence and PET analyses. The inconvenient of 
this method is that the HCC model has to express AFP. To avoid this problem hepatoma cell 
lines where engineered with luciferease (HCC-LM3) (Ma et al., 2011) or red luminescence 
www.intechopen.com
 
Hepatocellular Carcinoma – Basic Research 
 
346 
protein (Xiao et al., 2011). This approach to study CTC in the context of HCC is very 
promising, but the major problem is the sensitivity of the bioluminescence machine. This 
approach has not yet studied in the context of CTC in the blood or in organs other than liver. 
6. Conclusion 
There are two major problems to detect circulating hepatocarcinoma cells in the human 
blood. The first problem is the low number of specific markers known. The second problem 
is that few cells are present in the bloodstream. To overcome these problems, few years ago 
new approaches have been developed such as the techniques to study membrane proteins 
by mass spectrometry and the development of fluorescent hepatoma cells. 
Nowadays, these procedures are not suitable in clinical practice. However, it is undeniable 
that early detection of tumors and metastasis is urgently needed in medicine and these new 
exciting techniques and findings are changing our point of view of carcinogenesis very fast. 
In the future, CTC detection will certainly be an important diagnostic tool in cancer patients, 
providing a new and accurate assessment of lesion staging.  
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